Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Respiratory

PUBLISHER: Grand View Research | PRODUCT CODE: 1433625

Cover Image

PUBLISHER: Grand View Research | PRODUCT CODE: 1433625

Asthma Therapeutics Market Size, Share & Trends Analysis Report By Drug Class (Anti- inflammatory, Bronchodilators), By Product (Inhalers, Nebulizers), By Routeof Administration (Oral, Inhaled), By Region, And Segment Forecasts, 2024 - 2030

PUBLISHED:
PAGES: 150 Pages
DELIVERY TIME: 2-10 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF (Single User License)
USD 5950
Printable PDF (5-User License)
USD 6950
Printable PDF (Enterprise License)
USD 8950

Add to Cart

Description

Table of Contents

List of Tables

Asthma Therapeutics Market Growth & Trends:

The global asthma therapeutics market size is expected to reach USD 37.91 billion by 2030, expanding at a CAGR of 5.3% from 2024 to 2030, according to a new report by Grand View Research, Inc. The increasing prevalence of asthma coupled with the adoption of biologics as a long-term treatment option to treat the severe form of asthma is expected to offer this market with lucrative growth opportunities. According to the statistics published by the World Allergy Journal, in May 2014, patients suffering from asthma registered around 300 million and the number is expected to soar due to a large number of individuals inclining towards unhealthy dietary habits and sedentary lifestyles.

In addition, patent expiration of branded drugs, such as Singulair, Advair and other major drugs during the forecast period has led to a stiff generic competition, which will negatively impact the asthma therapeutics market growth in the coming years. On the contrary, the introduction of biologics is accruing towards the increasing market share of the asthma therapeutics segment, and is anticipated to continue during the forecast period.

The enhanced demand for personalized medicine approach as opposed to the conventional medication prescription pattern for treatment of severe asthma is anticipated to aid the emergence of asthma therapeutics market in the future. In addition, development of technologically advanced products, such as pressurized metered dose inhalers and smart inhalers, equipped with sensor technology and inbuilt wireless communication system is further expected to propel the asthma therapeutics market growth in the next seven years.

Asthma Therapeutics Market Report Highlights:

  • The anti-inflammatory drug class is expected to exhibit rapid growth of over the forecast period owing to the introduction of affordable and innovative biologics targeting the severe asthma condition. In addition, the awareness gained pertaining to the benefits rendered by the biologics and monoclonal antibodies is anticipated to exhibit an upward shift in the market expansion in the coming years.
  • The dry powder inhalers (DPIs) are expected to be the fastest growing segment due to the increasing adoption of these devices because of their high clinical efficiency than other inhalers. They are able to deliver both, small and large-sized drug components and dispense specialty engineered molecules. These related merits have spiked the adoption rates thereby contributing towards the risen market penetration.
  • Rising number of individuals opting for alternative treatment options, such as inhaled fixed-dose combination drugs for asthma medication is anticipated to serve this market with future growth opportunities.
  • Some of the key players operating in the asthma therapeutics market include AstraZeneca Plc, Philips Healthcare, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline Plc, Sanofi-Aventis SA, CareFusion Corporation, Sunovion Pharmaceuticals, Inc., Boehringer Ingelheim GmbH, Roche Diagnostics, and Merck& Co., Inc.
  • Market leaders are focusing on the introduction of technologically advanced devices and novel, improved biologics to gain a competitive advantage. The asthma therapeutics segment has a very strong pipeline as there are almost 100 novel molecules that are in the development phase and manufacturers are focusing on the development of personalized medication. The aforementioned factors collectively strengthen the industry growth in the near future.
  • For instance, drug molecules, such as Cinquil by Teva Pharmaceutical Industries Ltd., Lebrikizumab by Roche (Phase III), Mastinib by AB Science (Phase II/III), and Bosatria by GlaxoSmithKline Plc (Phase III), are in the development stage undergoing clinical research trials. Their commercial availability during the forecast period is expected to provide a boost to this vertical.
Show more
Product Code: 978-1-68038-936-4

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug Class
    • 1.2.2. Product
    • 1.2.3. Route of Administration
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for Primary Interviews in North America
      • 1.4.5.2. Data for Primary Interviews in Europe
      • 1.4.5.3. Data for Primary Interviews in Asia Pacific
      • 1.4.5.4. Data for Primary Interviews in Latin America
      • 1.4.5.5. Data for Primary Interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Drug class outlook
    • 2.2.2. Product outlook
    • 2.2.3. Rout of administration outlook
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Asthma Therapeutics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing incidence of asthma
      • 3.2.1.2. Emergence of novel biologics
      • 3.2.1.3. Rising awareness programs
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Patent expiration of branded drugs
      • 3.2.2.2. Regulatory challenges
  • 3.3. Asthma Therapeutics Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Asthma Therapeutics Market: Drug Class Estimates & Trend Analysis

  • 4.1. Drug Class Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global Asthma Therapeutics Market by Drug Class Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. Anti- inflammatory
      • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.4.2. Bronchodilators
      • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.4.3. Combination Therapy
      • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 5. Asthma Therapeutics Market: Product Estimates & Trend Analysis

  • 5.1. Product Market Share, 2023 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global Asthma Therapeutics Market by Product Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.4.1. Inhalers
      • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
      • 5.4.1.2. Dry Powder
      • 5.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
      • 5.4.1.3. Metered Dose
      • 5.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
      • 5.4.1.4. Soft Mist
      • 5.4.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 5.4.2. Nebulizers
      • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 6. Asthma Therapeutics Market: Route of Administration Estimates & Trend Analysis

  • 6.1. Route of Administration Market Share, 2023 & 2030
  • 6.2. Segment Dashboard
  • 6.3. Global Asthma Therapeutics Market by Route of Administration Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 6.4.1. Oral
      • 6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.4.2. Inhaled
      • 6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.4.3. Others
      • 6.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 7. Asthma Therapeutics Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2023 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Global Regional Market Snapshot
  • 7.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.5. North America
    • 7.5.1. U.S.
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.5.2. Canada
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.6. Europe
    • 7.6.1. Germany
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. Germany market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.6.2. UK
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. UK market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.6.3. France
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Regulatory framework/ reimbursement structure
      • 7.6.3.3. Competitive scenario
      • 7.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.6.4. Italy
      • 7.6.4.1. Key country dynamics
      • 7.6.4.2. Regulatory framework/ reimbursement structure
      • 7.6.4.3. Competitive scenario
      • 7.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.6.5. Spain
      • 7.6.5.1. Key country dynamics
      • 7.6.5.2. Regulatory framework/ reimbursement structure
      • 7.6.5.3. Competitive scenario
      • 7.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.6.6. Norway
      • 7.6.6.1. Key country dynamics
      • 7.6.6.2. Regulatory framework/ reimbursement structure
      • 7.6.6.3. Competitive scenario
      • 7.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.6.7. Sweden
      • 7.6.7.1. Key country dynamics
      • 7.6.7.2. Regulatory framework/ reimbursement structure
      • 7.6.7.3. Competitive scenario
      • 7.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.6.8. Denmark
      • 7.6.8.1. Key country dynamics
      • 7.6.8.2. Regulatory framework/ reimbursement structure
      • 7.6.8.3. Competitive scenario
      • 7.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.7. Asia Pacific
    • 7.7.1. Japan
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.7.2. China
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.7.3. India
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.7.4. South Korea
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. South Korea market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.7.5. Australia
      • 7.7.5.1. Key country dynamics
      • 7.7.5.2. Regulatory framework/ reimbursement structure
      • 7.7.5.3. Competitive scenario
      • 7.7.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.7.6. Thailand
      • 7.7.6.1. Key country dynamics
      • 7.7.6.2. Regulatory framework/ reimbursement structure
      • 7.7.6.3. Competitive scenario
      • 7.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.8. Latin America
    • 7.8.1. Brazil
      • 7.8.1.1. Key country dynamics
      • 7.8.1.2. Regulatory framework/ reimbursement structure
      • 7.8.1.3. Competitive scenario
      • 7.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.8.2. Mexico
      • 7.8.2.1. Key country dynamics
      • 7.8.2.2. Regulatory framework/ reimbursement structure
      • 7.8.2.3. Competitive scenario
      • 7.8.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.8.3. Argentina
      • 7.8.3.1. Key country dynamics
      • 7.8.3.2. Regulatory framework/ reimbursement structure
      • 7.8.3.3. Competitive scenario
      • 7.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.9. MEA
    • 7.9.1. South Africa
      • 7.9.1.1. Key country dynamics
      • 7.9.1.2. Regulatory framework/ reimbursement structure
      • 7.9.1.3. Competitive scenario
      • 7.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.9.2. Saudi Arabia
      • 7.9.2.1. Key country dynamics
      • 7.9.2.2. Regulatory framework/ reimbursement structure
      • 7.9.2.3. Competitive scenario
      • 7.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.9.3. UAE
      • 7.9.3.1. Key country dynamics
      • 7.9.3.2. Regulatory framework/ reimbursement structure
      • 7.9.3.3. Competitive scenario
      • 7.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.9.4. Kuwait
      • 7.9.4.1. Key country dynamics
      • 7.9.4.2. Regulatory framework/ reimbursement structure
      • 7.9.4.3. Competitive scenario
      • 7.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. List of key distributors and channel partners
    • 8.3.2. Key customers
    • 8.3.3. Key company market share analysis, 2023
    • 8.3.4. Teva Pharmaceutical Industries Ltd
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Product benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. GSK plc
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Product benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. Merck & Co., Inc.
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Product benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. F. Hoffmann-La Roche Ltd
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Product benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. AstraZeneca
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Product benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. Boehringer Ingelheim International GmbH
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Product benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. Sanofi
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Product benchmarking
      • 8.3.10.4. Strategic initiatives
    • 8.3.11. Koninklijke Philips N.V.
      • 8.3.11.1. Company overview
      • 8.3.11.2. Financial performance
      • 8.3.11.3. Product benchmarking
      • 8.3.11.4. Strategic initiatives
    • 8.3.12. BD
      • 8.3.12.1. Company overview
      • 8.3.12.2. Financial performance
      • 8.3.12.3. Product benchmarking
      • 8.3.12.4. Strategic initiatives
    • 8.3.13. Covis Pharma
      • 8.3.13.1. Company overview
      • 8.3.13.2. Financial performance
      • 8.3.13.3. Product benchmarking
      • 8.3.13.4. Strategic initiatives
Show more
Product Code: 978-1-68038-936-4

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America asthma therapeutics market, by region, 2018 - 2030 (USD Billion)
  • Table 3 North America asthma therapeutics market, by drug class, 2018 - 2030 (USD Billion)
  • Table 4 North America asthma therapeutics market, by product, 2018 - 2030 (USD Billion)
  • Table 5 North America asthma therapeutics market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 6 U.S. asthma therapeutics market, by drug class, 2018 - 2030 (USD Billion)
  • Table 7 U.S. asthma therapeutics market, by product, 2018 - 2030 (USD Billion)
  • Table 8 U.S. asthma therapeutics market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 9 Canada asthma therapeutics market, by drug class, 2018 - 2030 (USD Billion)
  • Table 10 Canada asthma therapeutics market, by product, 2018 - 2030 (USD Billion)
  • Table 11 Canada asthma therapeutics market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 12 Europe asthma therapeutics market, by region, 2018 - 2030 (USD Billion)
  • Table 13 Europe asthma therapeutics market, by drug class, 2018 - 2030 (USD Billion)
  • Table 14 Europe asthma therapeutics market, by product, 2018 - 2030 (USD Billion)
  • Table 15 Europe asthma therapeutics market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 16 Germany asthma therapeutics market, by drug class, 2018 - 2030 (USD Billion)
  • Table 17 Germany asthma therapeutics market, by product, 2018 - 2030 (USD Billion)
  • Table 18 Germany asthma therapeutics market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 19 UK asthma therapeutics market, by drug class, 2018 - 2030 (USD Billion)
  • Table 20 UK asthma therapeutics market, by product, 2018 - 2030 (USD Billion)
  • Table 21 UK asthma therapeutics market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 22 France asthma therapeutics market, by drug class, 2018 - 2030 (USD Billion)
  • Table 23 France asthma therapeutics market, by product, 2018 - 2030 (USD Billion)
  • Table 24 France asthma therapeutics market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 25 Italy asthma therapeutics market, by drug class, 2018 - 2030 (USD Billion)
  • Table 26 Italy asthma therapeutics market, by product, 2018 - 2030 (USD Billion)
  • Table 27 Italy asthma therapeutics market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 28 Spain asthma therapeutics market, by drug class, 2018 - 2030 (USD Billion)
  • Table 29 Spain asthma therapeutics market, by product, 2018 - 2030 (USD Billion)
  • Table 30 Spain asthma therapeutics market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 31 Denmark asthma therapeutics market, by drug class, 2018 - 2030 (USD Billion)
  • Table 32 Denmark asthma therapeutics market, by product, 2018 - 2030 (USD Billion)
  • Table 33 Denmark asthma therapeutics market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 34 Sweden asthma therapeutics market, by drug class, 2018 - 2030 (USD Billion)
  • Table 35 Sweden asthma therapeutics market, by product, 2018 - 2030 (USD Billion)
  • Table 36 Sweden asthma therapeutics market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 37 Norway asthma therapeutics market, by drug class, 2018 - 2030 (USD Billion)
  • Table 38 Norway asthma therapeutics market, by product, 2018 - 2030 (USD Billion)
  • Table 39 Norway asthma therapeutics market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 40 Asia Pacific asthma therapeutics market, by region, 2018 - 2030 (USD Billion)
  • Table 41 Asia Pacific asthma therapeutics market, by drug class, 2018 - 2030 (USD Billion)
  • Table 42 Asia Pacific asthma therapeutics market, by product, 2018 - 2030 (USD Billion)
  • Table 43 Asia Pacific asthma therapeutics market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 44 China asthma therapeutics market, by drug class, 2018 - 2030 (USD Billion)
  • Table 45 China asthma therapeutics market, by product, 2018 - 2030 (USD Billion)
  • Table 46 China asthma therapeutics market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 47 Japan asthma therapeutics market, by drug class, 2018 - 2030 (USD Billion)
  • Table 48 Japan asthma therapeutics market, by product, 2018 - 2030 (USD Billion)
  • Table 49 Japan asthma therapeutics market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 50 India asthma therapeutics market, by drug class, 2018 - 2030 (USD Billion)
  • Table 51 India asthma therapeutics market, by product, 2018 - 2030 (USD Billion)
  • Table 52 India asthma therapeutics market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 53 South Korea asthma therapeutics market, by drug class, 2018 - 2030 (USD Billion)
  • Table 54 South Korea asthma therapeutics market, by product, 2018 - 2030 (USD Billion)
  • Table 55 South Korea asthma therapeutics market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 56 Australia asthma therapeutics market, by drug class, 2018 - 2030 (USD Billion)
  • Table 57 Australia asthma therapeutics market, by product, 2018 - 2030 (USD Billion)
  • Table 58 Australia asthma therapeutics market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 59 Thailand asthma therapeutics market, by drug class, 2018 - 2030 (USD Billion)
  • Table 60 Thailand asthma therapeutics market, by product, 2018 - 2030 (USD Billion)
  • Table 61 Thailand asthma therapeutics market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 62 Latin America asthma therapeutics market, by product, 2018 - 2030 (USD Billion)
  • Table 63 Latin America asthma therapeutics market, by drug class, 2018 - 2030 (USD Billion)
  • Table 64 Latin America asthma therapeutics market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 65 Brazil asthma therapeutics market, by drug class, 2018 - 2030 (USD Billion)
  • Table 66 Brazil asthma therapeutics market, by product, 2018 - 2030 (USD Billion)
  • Table 67 Brazil asthma therapeutics market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 68 Mexico asthma therapeutics market, by drug class, 2018 - 2030 (USD Billion)
  • Table 69 Mexico asthma therapeutics market, by product, 2018 - 2030 (USD Billion)
  • Table 70 Mexico asthma therapeutics market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 71 Argentina asthma therapeutics market, by drug class, 2018 - 2030 (USD Billion)
  • Table 72 Argentina asthma therapeutics market, by product, 2018 - 2030 (USD Billion)
  • Table 73 Argentina asthma therapeutics market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 74 MEA asthma therapeutics market, by region, 2018 - 2030 (USD Billion)
  • Table 75 MEA asthma therapeutics market, by drug class, 2018 - 2030 (USD Billion)
  • Table 76 MEA asthma therapeutics market, by product, 2018 - 2030 (USD Billion)
  • Table 77 MEA asthma therapeutics market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 78 South Africa asthma therapeutics market, by drug class, 2018 - 2030 (USD Billion)
  • Table 79 South Africa asthma therapeutics market, by product, 2018 - 2030 (USD Billion)
  • Table 80 South Africa asthma therapeutics market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 81 Saudi Arabia asthma therapeutics market, by drug class, 2018 - 2030 (USD Billion)
  • Table 82 Saudi Arabia asthma therapeutics market, by product, 2018 - 2030 (USD Billion)
  • Table 83 Saudi Arabia asthma therapeutics market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 84 UAE asthma therapeutics market, by drug class, 2018 - 2030 (USD Billion)
  • Table 85 UAE asthma therapeutics market, by product, 2018 - 2030 (USD Billion)
  • Table 86 UAE asthma therapeutics market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 87 Kuwait asthma therapeutics market, by drug class, 2018 - 2030 (USD Billion)
  • Table 88 Kuwait asthma therapeutics market, by product, 2018 - 2030 (USD Billion)
  • Table 89 Kuwait asthma therapeutics market, by route of administration, 2018 - 2030 (USD Billion)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary Interviews in North America
  • Fig. 5 Primary Interviews in Europe
  • Fig. 6 Primary Interviews in APAC
  • Fig. 7 Primary Interviews in Latin America
  • Fig. 8 Primary Interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Asthma therapeutics market: market outlook
  • Fig. 14 Asthma therapeutics competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Penetration and growth prospect mapping
  • Fig. 18 Industry value chain analysis
  • Fig. 19 Asthma therapeutics market driver impact
  • Fig. 20 Asthma therapeutics market restraint impact
  • Fig. 21 Asthma therapeutics market strategic initiatives analysis
  • Fig. 22 Asthma therapeutics market: Drug class movement analysis
  • Fig. 23 Asthma therapeutics market: Drug class outlook and key takeaways
  • Fig. 24 Anti-inflammatory market estimates and forecast, 2018 - 2030
  • Fig. 25 Bronchodilators inhalers market estimates and forecast, 2018 - 2030
  • Fig. 26 Combination therapy inhalers market estimates and forecast, 2018 - 2030
  • Fig. 27 Asthma therapeutics market: Product movement analysis
  • Fig. 28 Asthma therapeutics market: Product outlook and key takeaways
  • Fig. 29 Inhalers market estimates and forecast, 2018 - 2030
  • Fig. 30 Dry powder inhalers market estimates and forecast, 2018 - 2030
  • Fig. 31 Metered dose inhalers market estimates and forecast, 2018 - 2030
  • Fig. 32 Soft mist inhalers market estimates and forecast, 2018 - 2030
  • Fig. 33 Nebulizers market estimates and forecast, 2018 - 2030
  • Fig. 34 Asthma therapeutics market: Route of administration movement analysis
  • Fig. 35 Asthma therapeutics market: Route of administration outlook and key takeaways
  • Fig. 36 Oral market estimates and forecasts, 2018 - 2030
  • Fig. 37 Inhaled market estimates and forecasts,2018 - 2030
  • Fig. 38 Others market estimates and forecasts, 2018 - 2030
  • Fig. 39 Global asthma therapeutics market: Regional movement analysis
  • Fig. 40 Global asthma therapeutics market: Regional outlook and key takeaways
  • Fig. 41 Global asthma therapeutics market shares and leading players
  • Fig. 42 North America market share and leading players
  • Fig. 43 Europe market share and leading players
  • Fig. 44 Asia Pacific market share and leading players
  • Fig. 45 Latin America market share and leading players
  • Fig. 46 Middle East & Africa market share and leading players
  • Fig. 47 North America: SWOT
  • Fig. 48 Europe SWOT
  • Fig. 49 Asia Pacific SWOT
  • Fig. 50 Latin America SWOT
  • Fig. 51 MEA SWOT
  • Fig. 52 North America, by country
  • Fig. 53 North America
  • Fig. 54 North America market estimates and forecasts, 2018 - 2030
  • Fig. 55 U.S. key country dynamics
  • Fig. 56 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 57 Canada key country dynamics
  • Fig. 58 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 59 Europe
  • Fig. 60 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 61 UK key country dynamics
  • Fig. 62 UK market estimates and forecasts, 2018 - 2030
  • Fig. 63 Germany key country dynamics
  • Fig. 64 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 65 France key country dynamics
  • Fig. 66 France market estimates and forecasts, 2018 - 2030
  • Fig. 67 Italy key country dynamics
  • Fig. 68 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 69 Spain key country dynamics
  • Fig. 70 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 71 Denmark key country dynamics
  • Fig. 72 Denmark market estimates and forecasts, 2018 - 2030
  • Fig. 73 Sweden key country dynamics
  • Fig. 74 Sweden market estimates and forecasts, 2018 - 2030
  • Fig. 75 Norway key country dynamics
  • Fig. 76 Norway market estimates and forecasts, 2018 - 2030
  • Fig. 77 Asia Pacific
  • Fig. 78 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 79 China key country dynamics
  • Fig. 80 China market estimates and forecasts, 2018 - 2030
  • Fig. 81 Japan key country dynamics
  • Fig. 82 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 83 India key country dynamics
  • Fig. 84 India market estimates and forecasts, 2018 - 2030
  • Fig. 85 Thailand key country dynamics
  • Fig. 86 Thailand market estimates and forecasts, 2018 - 2030
  • Fig. 87 South Korea key country dynamics
  • Fig. 88 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 89 Australia key country dynamics
  • Fig. 90 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 91 Latin America
  • Fig. 92 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 93 Brazil key country dynamics
  • Fig. 94 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 95 Mexico key country dynamics
  • Fig. 96 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 97 Argentina key country dynamics
  • Fig. 98 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 99 Middle East and Africa
  • Fig. 100 Middle East and Africa market estimates and forecasts, 2018 - 2030
  • Fig. 101 South Africa key country dynamics
  • Fig. 102 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 103 Saudi Arabia key country dynamics
  • Fig. 104 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 105 UAE key country dynamics
  • Fig. 106 UAE market estimates and forecasts, 2018 - 2030
  • Fig. 107 Kuwait key country dynamics
  • Fig. 108 Kuwait market estimates and forecasts, 2018 - 2030
  • Fig. 109 Market share of key market players - Asthma therapeutics market
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!